{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-24-000004","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.290434+00:00","generated_at":"2026-06-07T00:58:39.457663+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Autolus appoints Robert Azelby to Board, commercial focus as BLA for obe-cel submitted","bullets":["Robert W. Azelby appointed Class II director effective Jan 9, 2024; brings 30+ years biopharma commercial experience.","Initial option grant of 80,000 ADSs at $6.84/share; annual retainer £52,500 plus £3,500 for committee service.","Azelby was CEO of Eliem Therapeutics and Alder BioPharmaceuticals; served at Juno and Amgen.","Company recently submitted BLA for lead CAR T therapy obe-cel; Azelby to aid commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-24-000004","json":"https://secwatch.observer/filing/0001730463-24-000004.json","markdown":"https://secwatch.observer/filing/0001730463-24-000004.md","text":"https://secwatch.observer/filing/0001730463-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000004/0001730463-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000004/autl-20240109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:58:39.457663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06edc40385","claim":"Robert W. Azelby was appointed as Class II director at Autolus Therapeutics plc.","evidence_excerpt":"appointed Robert (“Bob”) W. Azelby to serve as a Class II director of the Company, effective January 9, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000004/0001730463-24-000004-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}